GT201300292A - Formulaciones peptídicas de liberación controlada. - Google Patents

Formulaciones peptídicas de liberación controlada.

Info

Publication number
GT201300292A
GT201300292A GT201300292A GT201300292A GT201300292A GT 201300292 A GT201300292 A GT 201300292A GT 201300292 A GT201300292 A GT 201300292A GT 201300292 A GT201300292 A GT 201300292A GT 201300292 A GT201300292 A GT 201300292A
Authority
GT
Guatemala
Prior art keywords
weight
controlled release
administration
peptide formulations
formulations
Prior art date
Application number
GT201300292A
Other languages
English (en)
Inventor
Fredrik Tiberg
Catalin Nistor
Markus Johnsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201300292(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201300292A publication Critical patent/GT201300292A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES QUE DORMAN UNA MEZCLA DE BAJA VISCOSIDAD DE:A) 20-80% EN PESO DE POR LO MENOS UN DIACILGLICEROL Y/O UN TOCOFEROL;B) 20-80% EN PESO DE POR LO MENOS UNA FOSFATIDILCOLINA (PC);C) 5-20% EN PESO DE POR LO MENOS UN SOLVENTE MONO-ALCOHÓLICO ORGÁNICO, BIOCOMPATIBLE;D) HASTA 20% EN PESO DE SOLVENTE POLARE) POR LO MENOS UN AGENTE ACTIVO PEPTÍDICO;F) OPCIONALMENTE POR LO MENOS UN ANTIOXIDANTE; DONDE LA RELACIÓN DE COMPONENTES A:B ESTÁ DENTRO DEL RANGO ENTRE 40:60 Y 54:46; DONDE LA PREFORMULACIÓN FORMA, O ES CAPAZ DE FORMAR, POR LO MENOS UNA ESTRUCTURA DE FASE CRISTALINA LÍQUIDA LUEGO DEL CONTACTO CON FLUIDO ACUOSO EN EXCESO.LA INVENCIÓN SE REFIERE ADEMÁS A MÉTODOS DE TRATAMIENTO QUE COMPRENDEN LA ADMINISTRACIÓN DE ESE TIPO DE COMPOSICIONES, Y SE REFIERE A DISPOSITIVOS Y KITS DE ADMINISTRACIÓN PRECARGADOS QUE CONTIENEN LAS FORMULACIONES.
GT201300292A 2011-05-25 2013-11-22 Formulaciones peptídicas de liberación controlada. GT201300292A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161489886P 2011-05-25 2011-05-25

Publications (1)

Publication Number Publication Date
GT201300292A true GT201300292A (es) 2014-08-05

Family

ID=46456496

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300292A GT201300292A (es) 2011-05-25 2013-11-22 Formulaciones peptídicas de liberación controlada.

Country Status (28)

Country Link
US (2) US11433120B2 (es)
EP (1) EP2714004B1 (es)
JP (2) JP6265888B2 (es)
KR (1) KR102066755B1 (es)
CN (2) CN108283619B (es)
AR (1) AR086577A1 (es)
AU (2) AU2012260821B2 (es)
BR (1) BR112013030104A8 (es)
CA (1) CA2836847C (es)
CL (1) CL2013003365A1 (es)
CO (1) CO6900117A2 (es)
CR (1) CR20130653A (es)
CU (1) CU20130158A7 (es)
DK (1) DK2714004T3 (es)
DO (1) DOP2013000275A (es)
EA (1) EA036213B1 (es)
EC (1) ECSP13013107A (es)
GT (1) GT201300292A (es)
IL (1) IL229376B (es)
MX (1) MX361716B (es)
MY (1) MY177820A (es)
NI (1) NI201300127A (es)
PE (1) PE20141484A1 (es)
PH (1) PH12013502550B1 (es)
SG (1) SG194865A1 (es)
TW (1) TWI624271B (es)
WO (1) WO2012160213A1 (es)
ZA (1) ZA201309653B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1768650B1 (en) * 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
US9107904B2 (en) 2012-04-05 2015-08-18 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
MX350964B (es) * 2012-05-25 2017-09-27 Camurus Ab Formulaciones de agonistas del receptor de somatostatina.
EP2877155B1 (en) 2012-07-26 2020-10-28 Camurus AB Opioid formulations
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
CA3036307A1 (en) 2016-09-15 2018-03-22 Camurus Ab Prostacyclin analogue formulations
CN109789215B (zh) * 2016-09-27 2022-12-16 卡姆拉斯公司 含有生长激素抑制素受体激动剂的制剂
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
CN112188898A (zh) * 2017-11-15 2021-01-05 节奏制药公司 缓释肽配制品
CN109091451B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 亲水性药物的油相液晶凝胶前体制剂及其制备方法
CN113993535A (zh) * 2019-05-29 2022-01-28 卡姆拉斯公司 脂质控释组合物
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法
JP2024517204A (ja) * 2021-05-04 2024-04-19 カムルス エービー 神経内分泌腫瘍を治療するための組成物及び方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046642A1 (en) * 2003-11-07 2005-05-26 Camurus Ab Compositions of lipids and cationic peptides
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
EP1768650B1 (en) * 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
GB0417388D0 (en) 2004-08-04 2004-09-08 Camurus Ab Composition
KR101234885B1 (ko) 2004-08-04 2013-02-19 카무러스 에이비 비층상 분산을 형성하는 조성물
ES2343641T3 (es) * 2005-01-14 2010-08-05 Camurus Ab Formulaciones bioadhesivas topicas.
PL1843746T3 (pl) * 2005-01-14 2011-09-30 Camurus Ab Formulacje analogów somatostatyny
EP1843751B1 (en) * 2005-01-21 2020-09-30 Camurus Ab Pharmaceutical lipid compositions
ATE509634T1 (de) * 2005-04-08 2011-06-15 Amylin Pharmaceuticals Inc Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
DK1888031T3 (da) * 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
US8931272B2 (en) * 2010-10-29 2015-01-13 Ford Global Technologies, Llc Method and system for limiting output of a boosted engine
BR112014013693B1 (pt) * 2011-12-05 2023-01-31 Camurus Ab Pré-formulação, e, uso de uma pré-formulação
MX350964B (es) * 2012-05-25 2017-09-27 Camurus Ab Formulaciones de agonistas del receptor de somatostatina.
US20230285502A1 (en) * 2016-09-07 2023-09-14 Camurus Ab Mixtures and formulations
CN109789215B (zh) * 2016-09-27 2022-12-16 卡姆拉斯公司 含有生长激素抑制素受体激动剂的制剂

Also Published As

Publication number Publication date
MX2013013401A (es) 2013-12-12
US20140162944A1 (en) 2014-06-12
ECSP13013107A (es) 2015-03-31
US11433120B2 (en) 2022-09-06
AR086577A1 (es) 2014-01-08
CU20130158A7 (es) 2014-04-24
CR20130653A (es) 2014-03-05
BR112013030104A2 (pt) 2016-09-20
CA2836847A1 (en) 2012-11-29
JP6415673B2 (ja) 2018-10-31
CN108283619A (zh) 2018-07-17
NZ617828A (en) 2016-11-25
IL229376B (en) 2019-11-28
CN103702662B (zh) 2018-07-20
MX361716B (es) 2018-12-14
EP2714004A1 (en) 2014-04-09
PE20141484A1 (es) 2014-10-31
NI201300127A (es) 2014-02-25
CO6900117A2 (es) 2014-03-20
JP2018076327A (ja) 2018-05-17
AU2012260821B2 (en) 2016-01-07
ZA201309653B (en) 2016-05-25
KR102066755B1 (ko) 2020-01-15
PH12013502550A1 (en) 2015-08-10
WO2012160213A1 (en) 2012-11-29
AU2016202156A1 (en) 2016-04-28
CA2836847C (en) 2021-06-29
EA201391675A1 (ru) 2014-08-29
US20210308226A1 (en) 2021-10-07
BR112013030104A8 (pt) 2021-09-08
CL2013003365A1 (es) 2014-07-25
MY177820A (en) 2020-09-23
JP2014520090A (ja) 2014-08-21
EA036213B1 (ru) 2020-10-14
PH12013502550B1 (en) 2015-08-10
CN103702662A (zh) 2014-04-02
DK2714004T3 (da) 2024-06-10
CN108283619B (zh) 2021-09-14
AU2016202156B2 (en) 2018-03-22
EP2714004B1 (en) 2024-05-15
KR20140045438A (ko) 2014-04-16
JP6265888B2 (ja) 2018-01-24
TW201249463A (en) 2012-12-16
TWI624271B (zh) 2018-05-21
SG194865A1 (en) 2013-12-30
DOP2013000275A (es) 2014-05-15
IL229376A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
GT201300292A (es) Formulaciones peptídicas de liberación controlada.
CL2018003452A1 (es) Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides.
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
ECSP14012676A (es) Compuestos de carbamato y preparación y uso de los mismos
PE20141297A1 (es) Formulaciones peptidicas robustas de liberacion controlada
BR112021002069A2 (pt) Composição para tratamento capilar, métodos e usos da mesma.
GT201100195A (es) Derivados de sulfonamida
AR083016A1 (es) Formulaciones liquidas para la agricultura con una mejor estabilidad
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2016002881A (es) Moduladores del canal de sodio para el tratamiento de dolor y diabetes.
ECSP17025302A (es) N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b
CL2017000120A1 (es) Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares
AR106049A1 (es) Formulaciones de liberación controlada
GT201600060A (es) Formulaciones de espuma y aparatos para suminstro
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
BR112017013471A2 (pt) Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit.
BR112012015433A2 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
AR106364A1 (es) Derivados de insulina y sus usos médicos
NI201100201A (es) Metodo y composición para el control de parásitos
DOP2015000137A (es) Dispersión sólida de un modulador selectivo de los receptores de progesterona
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
UY35338A (es) Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
AR099097A1 (es) SUSPOEMULSIÓN ACUOSA QUE CONTIENE l-CIALOTRINA Y MÉTODOS PARA PRODUCIR Y USAR LA MISMA